 Paul Maroni
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 39 | 2024 | 1048 | 3.800 |
Why?
| | Prostatectomy | 8 | 2019 | 102 | 1.500 |
Why?
| | Testicular Neoplasms | 7 | 2023 | 115 | 1.100 |
Why?
| | Urology | 3 | 2020 | 61 | 0.850 |
Why?
| | Embolism | 1 | 2021 | 43 | 0.690 |
Why?
| | Urethra | 1 | 2021 | 56 | 0.690 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 79 | 0.680 |
Why?
| | Androgen Antagonists | 4 | 2024 | 93 | 0.670 |
Why?
| | Laser Therapy | 1 | 2021 | 127 | 0.620 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1052 | 0.460 |
Why?
| | Kidney Medulla | 2 | 2005 | 31 | 0.460 |
Why?
| | Early Detection of Cancer | 5 | 2023 | 441 | 0.410 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 419 | 0.370 |
Why?
| | Urination Disorders | 1 | 2011 | 14 | 0.360 |
Why?
| | Prostate-Specific Antigen | 8 | 2020 | 166 | 0.360 |
Why?
| | Male | 56 | 2024 | 69783 | 0.340 |
Why?
| | Prostate | 7 | 2023 | 173 | 0.330 |
Why?
| | Oxalates | 2 | 2008 | 11 | 0.310 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2014 | 1556 | 0.280 |
Why?
| | Neoplasm Grading | 5 | 2021 | 316 | 0.280 |
Why?
| | Adenocarcinoma | 3 | 2022 | 892 | 0.270 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 219 | 0.260 |
Why?
| | Humans | 59 | 2024 | 141187 | 0.250 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1398 | 0.240 |
Why?
| | Kidney Tubules, Collecting | 1 | 2005 | 27 | 0.230 |
Why?
| | Oxalic Acid | 1 | 2004 | 4 | 0.230 |
Why?
| | Brachytherapy | 2 | 2016 | 130 | 0.220 |
Why?
| | Clinical Competence | 1 | 2012 | 1202 | 0.210 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 256 | 0.210 |
Why?
| | Androgens | 4 | 2024 | 187 | 0.190 |
Why?
| | Paraganglioma | 1 | 2022 | 53 | 0.180 |
Why?
| | Cell Hypoxia | 2 | 2015 | 231 | 0.180 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2022 | 89 | 0.180 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 109 | 0.170 |
Why?
| | Prolactin | 3 | 1997 | 96 | 0.170 |
Why?
| | Adaptor Proteins, Vesicular Transport | 2 | 1997 | 46 | 0.170 |
Why?
| | Surveys and Questionnaires | 3 | 2017 | 5929 | 0.170 |
Why?
| | Orchiectomy | 3 | 2016 | 75 | 0.160 |
Why?
| | Aged | 21 | 2021 | 24574 | 0.160 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2020 | 26 | 0.160 |
Why?
| | Middle Aged | 20 | 2021 | 34434 | 0.160 |
Why?
| | Risk Assessment | 4 | 2020 | 3490 | 0.160 |
Why?
| | Salvage Therapy | 2 | 2018 | 153 | 0.160 |
Why?
| | Proanthocyanidins | 1 | 2019 | 9 | 0.150 |
Why?
| | Biflavonoids | 1 | 2019 | 9 | 0.150 |
Why?
| | Stromal Cells | 1 | 2019 | 117 | 0.150 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.150 |
Why?
| | Catechin | 1 | 2019 | 26 | 0.150 |
Why?
| | Hospitals | 2 | 2023 | 696 | 0.150 |
Why?
| | Anthocyanins | 1 | 2019 | 35 | 0.150 |
Why?
| | Grape Seed Extract | 1 | 2019 | 43 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 58 | 0.140 |
Why?
| | Digital Rectal Examination | 1 | 2018 | 11 | 0.140 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2018 | 35 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 1997 | 429 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1073 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 192 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1997 | 132 | 0.130 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 194 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 14 | 0.130 |
Why?
| | Biopsy, Needle | 2 | 2016 | 187 | 0.130 |
Why?
| | Surgical Wound Infection | 2 | 2019 | 319 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.130 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.130 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 674 | 0.130 |
Why?
| | Plant Extracts | 1 | 2018 | 209 | 0.130 |
Why?
| | Radiology | 1 | 2019 | 170 | 0.120 |
Why?
| | Liver | 4 | 1997 | 1819 | 0.120 |
Why?
| | Spectrum Analysis | 1 | 2016 | 92 | 0.120 |
Why?
| | Medical Oncology | 1 | 2019 | 316 | 0.120 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.120 |
Why?
| | Prognosis | 7 | 2019 | 4073 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2015 | 73 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 2 | 1997 | 623 | 0.110 |
Why?
| | Risk | 2 | 2015 | 904 | 0.110 |
Why?
| | Lymphatic Metastasis | 3 | 2014 | 326 | 0.110 |
Why?
| | HSP70 Heat-Shock Proteins | 2 | 2008 | 74 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 400 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 147 | 0.110 |
Why?
| | Biopsy | 4 | 2023 | 1081 | 0.110 |
Why?
| | Genomics | 1 | 2019 | 814 | 0.110 |
Why?
| | Leydig Cell Tumor | 1 | 2014 | 8 | 0.110 |
Why?
| | Cause of Death | 1 | 2016 | 440 | 0.110 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 21 | 0.100 |
Why?
| | Priapism | 1 | 2013 | 11 | 0.100 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
| | Optics and Photonics | 1 | 2014 | 42 | 0.100 |
Why?
| | Hypertension | 1 | 2022 | 1252 | 0.100 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 19 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 167 | 0.100 |
Why?
| | Extracellular Vesicles | 1 | 2015 | 152 | 0.100 |
Why?
| | Triglycerides | 1 | 2015 | 514 | 0.100 |
Why?
| | Proline | 1 | 2013 | 76 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2010 | 133 | 0.100 |
Why?
| | Treatment Outcome | 7 | 2018 | 11120 | 0.100 |
Why?
| | Neoplasm Invasiveness | 4 | 2016 | 509 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 406 | 0.090 |
Why?
| | Telephone | 1 | 2013 | 182 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2087 | 0.090 |
Why?
| | Signal Transduction | 4 | 2004 | 5144 | 0.090 |
Why?
| | Survival Rate | 4 | 2017 | 1970 | 0.090 |
Why?
| | Urothelium | 1 | 2011 | 37 | 0.090 |
Why?
| | Cell Line | 3 | 2008 | 2885 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2014 | 502 | 0.090 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 41 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 76 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1171 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2008 | 183 | 0.080 |
Why?
| | Spinal Fractures | 1 | 2011 | 74 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2008 | 1110 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2022 | 215 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2010 | 56 | 0.080 |
Why?
| | Oxygen | 1 | 2015 | 993 | 0.080 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1243 | 0.080 |
Why?
| | Survival Analysis | 2 | 2016 | 1319 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2020 | 7856 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1041 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2009 | 281 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 150 | 0.080 |
Why?
| | Counseling | 1 | 2013 | 398 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2019 | 2797 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 961 | 0.080 |
Why?
| | Lymph Node Excision | 2 | 2014 | 169 | 0.080 |
Why?
| | Carcinoma | 1 | 2011 | 230 | 0.080 |
Why?
| | Survivors | 1 | 2013 | 501 | 0.080 |
Why?
| | Lymphatic Diseases | 1 | 2009 | 22 | 0.080 |
Why?
| | Cystitis | 1 | 2009 | 23 | 0.070 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 37 | 0.070 |
Why?
| | Age Factors | 4 | 2017 | 3292 | 0.070 |
Why?
| | Logistic Models | 3 | 2019 | 2086 | 0.070 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.070 |
Why?
| | Patient Selection | 2 | 2018 | 688 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2013 | 778 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 1261 | 0.070 |
Why?
| | Databases, Factual | 3 | 2019 | 1444 | 0.070 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 3469 | 0.070 |
Why?
| | Image-Guided Biopsy | 2 | 2020 | 39 | 0.070 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 170 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 286 | 0.060 |
Why?
| | Kidney Tubules, Proximal | 1 | 2008 | 132 | 0.060 |
Why?
| | Societies, Medical | 1 | 2011 | 855 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 174 | 0.060 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 326 | 0.060 |
Why?
| | Time Factors | 4 | 2014 | 6956 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2008 | 378 | 0.060 |
Why?
| | Adult | 12 | 2020 | 39177 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2018 | 281 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2009 | 630 | 0.060 |
Why?
| | Animals | 11 | 2022 | 37657 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2016 | 5200 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2010 | 1330 | 0.060 |
Why?
| | Young Adult | 6 | 2020 | 13673 | 0.060 |
Why?
| | Isoflavones | 1 | 2005 | 26 | 0.060 |
Why?
| | Ear, Inner | 1 | 2005 | 50 | 0.060 |
Why?
| | Support Vector Machine | 2 | 2016 | 38 | 0.060 |
Why?
| | Mitotic Index | 2 | 2015 | 24 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 220 | 0.060 |
Why?
| | Body Fluids | 1 | 2005 | 70 | 0.060 |
Why?
| | Mice | 4 | 2022 | 18048 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 326 | 0.060 |
Why?
| | Urinary Incontinence | 1 | 2005 | 65 | 0.050 |
Why?
| | Growth | 1 | 2004 | 52 | 0.050 |
Why?
| | Informed Consent | 1 | 2006 | 189 | 0.050 |
Why?
| | MAP Kinase Signaling System | 2 | 2008 | 325 | 0.050 |
Why?
| | Disease Progression | 2 | 2018 | 2793 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 405 | 0.050 |
Why?
| | Propensity Score | 2 | 2016 | 328 | 0.050 |
Why?
| | United States | 5 | 2019 | 15220 | 0.050 |
Why?
| | Mass Screening | 2 | 2015 | 1310 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1490 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2019 | 2504 | 0.050 |
Why?
| | Receptors, Nicotinic | 1 | 2005 | 344 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 1997 | 431 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 908 | 0.050 |
Why?
| | Transcriptional Regulator ERG | 1 | 2022 | 17 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2166 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2004 | 194 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1973 | 0.050 |
Why?
| | Rats, Wistar | 3 | 1997 | 454 | 0.040 |
Why?
| | Rats | 6 | 2005 | 5629 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2022 | 119 | 0.040 |
Why?
| | Intestines | 1 | 2004 | 357 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1129 | 0.040 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1997 | 12 | 0.040 |
Why?
| | Shc Signaling Adaptor Proteins | 2 | 1997 | 12 | 0.040 |
Why?
| | Testosterone | 2 | 2015 | 404 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2001 | 274 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2001 | 120 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2022 | 204 | 0.040 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1251 | 0.040 |
Why?
| | Fever | 1 | 2001 | 308 | 0.040 |
Why?
| | Adolescent | 5 | 2022 | 22007 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 218 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 333 | 0.040 |
Why?
| | Reperfusion | 2 | 1996 | 44 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2001 | 316 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2890 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2005 | 681 | 0.040 |
Why?
| | Jagged-1 Protein | 1 | 2019 | 23 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2023 | 16273 | 0.040 |
Why?
| | Geography | 1 | 2019 | 201 | 0.040 |
Why?
| | Receptor, Notch1 | 1 | 2019 | 65 | 0.040 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 17 | 0.040 |
Why?
| | Zinc | 1 | 2022 | 299 | 0.040 |
Why?
| | Tissue Kallikreins | 1 | 2018 | 2 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 109 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 54 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 2019 | 77 | 0.040 |
Why?
| | Enzyme Activation | 4 | 2008 | 811 | 0.040 |
Why?
| | Kallikreins | 1 | 2018 | 27 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2001 | 454 | 0.040 |
Why?
| | Quality of Life | 2 | 2013 | 2999 | 0.030 |
Why?
| | Janus Kinase 2 | 1 | 1997 | 32 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1997 | 90 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2022 | 740 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2005 | 4208 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 1997 | 75 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 137 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 959 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 48 | 0.030 |
Why?
| | Phosphorylation | 4 | 2008 | 1768 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 565 | 0.030 |
Why?
| | Phenotype | 3 | 2010 | 3166 | 0.030 |
Why?
| | Protein Kinase C | 2 | 1994 | 252 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7739 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 755 | 0.030 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 31 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 48 | 0.030 |
Why?
| | Altitude | 1 | 2019 | 475 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 134 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2019 | 582 | 0.030 |
Why?
| | Ischemia | 2 | 1996 | 415 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1995 | 136 | 0.030 |
Why?
| | Proteins | 2 | 1997 | 1010 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 715 | 0.030 |
Why?
| | Female | 7 | 2021 | 75515 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 990 | 0.030 |
Why?
| | Colorado | 2 | 2015 | 4610 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 78 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1737 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 310 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 691 | 0.030 |
Why?
| | Needles | 1 | 2014 | 63 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 10438 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 220 | 0.020 |
Why?
| | Radiotherapy | 1 | 2014 | 208 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 90 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1995 | 415 | 0.020 |
Why?
| | Aging | 3 | 2010 | 1892 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 367 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1995 | 393 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 525 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 528 | 0.020 |
Why?
| | Child | 3 | 2022 | 22308 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1086 | 0.020 |
Why?
| | Reoperation | 1 | 2014 | 588 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 481 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 482 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2011 | 310 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 317 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 193 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2574 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 417 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1082 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 510 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5799 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2001 | 159 | 0.020 |
Why?
| | Prostatitis | 1 | 2009 | 18 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 58 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 34 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 567 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 1018 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2794 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 633 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1306 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2009 | 140 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 25 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 987 | 0.020 |
Why?
| | Immunoblotting | 2 | 2001 | 310 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 57 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3709 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2013 | 677 | 0.020 |
Why?
| | Tyrosine | 2 | 2001 | 228 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1336 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2009 | 153 | 0.020 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 139 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1234 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2009 | 211 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1820 | 0.020 |
Why?
| | Glutathione | 1 | 2009 | 356 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2008 | 2828 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2180 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 162 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 626 | 0.020 |
Why?
| | Phosphotyrosine | 2 | 1996 | 40 | 0.020 |
Why?
| | Models, Animal | 1 | 2008 | 396 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1365 | 0.010 |
Why?
| | Chinchilla | 1 | 2005 | 34 | 0.010 |
Why?
| | Equol | 1 | 2005 | 5 | 0.010 |
Why?
| | Guinea Pigs | 1 | 2005 | 171 | 0.010 |
Why?
| | Swine | 1 | 2008 | 806 | 0.010 |
Why?
| | Antioxidants | 1 | 2009 | 595 | 0.010 |
Why?
| | Bladder Exstrophy | 1 | 2004 | 17 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 2004 | 25 | 0.010 |
Why?
| | Bicarbonates | 1 | 2004 | 45 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2013 | 1128 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1498 | 0.010 |
Why?
| | Meat | 1 | 2005 | 93 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4174 | 0.010 |
Why?
| | Meningomyelocele | 1 | 2004 | 60 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6275 | 0.010 |
Why?
| | Body Height | 1 | 2004 | 196 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2746 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 1164 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 798 | 0.010 |
Why?
| | Receptor, IGF Type 1 | 1 | 2001 | 64 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9818 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11457 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 494 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2001 | 863 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2599 | 0.010 |
Why?
| | ErbB Receptors | 1 | 2001 | 610 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2741 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 4013 | 0.010 |
Why?
| | GRB2 Adaptor Protein | 1 | 1996 | 13 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1996 | 44 | 0.010 |
Why?
| | Neurons | 1 | 2005 | 1619 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 159 | 0.010 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 215 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2520 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 255 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1995 | 167 | 0.010 |
Why?
| | Phosphotransferases | 1 | 1994 | 24 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1994 | 98 | 0.010 |
Why?
| | Densitometry | 1 | 1994 | 38 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 284 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1994 | 114 | 0.010 |
Why?
| | Ornithine Decarboxylase | 1 | 1994 | 13 | 0.010 |
Why?
| | Genes, myc | 1 | 1994 | 48 | 0.010 |
Why?
| | Molecular Weight | 1 | 1994 | 329 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 336 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 230 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1994 | 385 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1652 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1996 | 968 | 0.010 |
Why?
| | Gene Expression | 1 | 1994 | 1491 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1994 | 1448 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1995 | 2002 | 0.000 |
Why?
|
|
Maroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|